<DOC>
	<DOCNO>NCT00325234</DOCNO>
	<brief_summary>The primary purpose study help answer follow research question : - whether chemotherapy combination therapy Pemetrexed-Carboplatin Gemcitabine-Vinorelbine help participant advance breast cancer make tumor small disappear long - learn side effect chemotherapy combination treatment arm - ass participant advance breast cancer report health change receive chemotherapy combination arm</brief_summary>
	<brief_title>Pemetrexed-Carboplatin Gemcitabine-Vinorelbine Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Females histologic cytologic diagnosis advance breast cancer . Lesions amenable surgery radiation curative intent . Performance status 0 2 Eastern Cooperative Oncology Group ( ECOG ) performance status scale . One prior chemotherapy contain anthracyclines ( neo ) adjuvant palliative 1stline treatment . One prior chemotherapy contain taxanes ( neo ) adjuvant palliative 1stline treatment . Prior radiation therapy allow less 25 % bone marrow . Participants must recover toxic effect treatment prior study enrollment ( except alopecia ) . Prior radiotherapy must complete 30 day study entry . Lesions radiate included site measurable disease unless clear tumor progression document lesion since end radiation therapy . At least one unidimensionally measurable lesion meeting Response Evaluation Criteria Solid Tumors ( RECIST ) criterion . Positron emission tomography [ PET ] scan ultrasound may use . Antitumoral hormonal treatment must discontinue prior enrollment . Estimated life expectancy least 3 month . Participant compliance geographic proximity allow adequate followup . Adequate organ function Female participant childbearing potential must test negative pregnancy within 7 day enrollment base urine and/or serum pregnancy test agree use reliable method birth control 6 month follow last dose study drug . Participants must sign informed consent document . Female participant must least 18 year age . Have receive treatment within last 30 day drug receive regulatory approval indication time study entry . Have previously complete withdrawn study study investigate Pemetrexed , Gemcitabine , Carboplatin Vinorelbine Have receive one line chemotherapy Metastatic Breast Cancer . Participants receive one combination anthracycline plus taxane . Are pregnant breastfeeding . Have serious concomitant systemic disorder ( e.g. , active infection ) , opinion investigator , would compromise safety participant compromise participant 's ability complete study . Have prior malignancy breast cancer , carcinoma situ cervix , nonmelanoma skin cancer , unless prior malignancy diagnose definitively treat least 5 year previously subsequent evidence recurrence . Are unable interrupt aspirin nonsteroidal antiinflammatory agent 5day period ( 8day period longacting agent piroxicam ) , unless Creatinine Clearance great equal 80 ml/min . Have central nervous system ( CNS ) metastasis . Have clinically relevant ( physical exam ) thirdspace fluid collection ( example , ascites pleural effusion ) control drainage procedure prior study entry . Are unable unwilling take folic acid , vitamin B12 supplementation , dexamethasone . Concurrent administration antitumor therapy .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>